A rational vaccine pipeline for tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 12, 2012, Pages 1566-1573

  Brennan, M J ^a   Stone, M R ^a,b   Evans, T ^a  

^a Global Affairs   (United States)

^b Liquidia Technologies Inc   (United States)

Author keywords

Mycobacterium tuberculosis; Tuberculosis; Vaccines

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; DNA VACCINE; RECOMBINANT FUSION POLYPROTEIN VACCINE; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG QUALITY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ENDEMIC DISEASES; HUMANS; IMMUNIZATION; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84870329077     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0569     Document Type: Review

References (51)

1. Xing Z, McFarland C T, Sallenave J M, Izzo A, Wang J, McMurray D N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 2009; 4: e5856.
2. McShane H, Pathan A A, Sander C R, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-1244.
3. Abel B, Tameris M, Mansoor N, et al. The novel TB vaccine, AERAS-402, induces robust and polyfunctional CD4 and CD8 T cells in adults. Am J Respir Crit Care Med 2010; 181: 1407-1417.
4. Christensen D, Lindenstrom T, van de Wijdeven G, Andersen P, Agger E M. Syringe free vaccination with CAF01 adjuvated Ag85B-ESAT-6 in bioneedles provides strong and prolonged protection against tuberculosis. PLoS ONE 2010; 5: e15043.
5. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the M. tuberculosis 72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010; 17: 1763-1771.
6. Aagaard C, Hoang T T, Izzo A, et al. Protection and polyfunctional T-cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 2009; 4: e5930.
7. van Dissel J T, Soonawala D, Joosten S A, et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T-cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011; 29: 2100-2109.
8. Lin P L, Dietrich J, Tan E, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2011; 122: 303-314.
9. Bertholet S, Ireton G C, Kahn M, et al. Identification of human T-cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008; 181: 7948-7957.
10. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann S H. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011; 204: 1573-1584.
11. Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010; 28: 1106-1116.
12. Patel N, Deshpande M M, Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002; 100: 191-193.
13. Stop TB Partnership Working Group, World Health Organization. New TB vaccines. Geneva, Switzerland: WHO, 2011. http://www.stoptb.org/wg/new-vaccines/ assets/documents/TB%20Vaccine%20Pipeline-rAug%202012.pdf Accessed September 2012.
14. Hawkridge T, Mahomed H. Prospects for a new, safer and more effective TB vaccine. Paediatr Respir Rev 2011; 12: 46-51.
15. Ottenhoff T H, Kaufmann S H. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012; 8: e1002607.
16. Hatherill M, Verver S, Mahomed H. Taskforce on clinical research issues STPWGoTV. Consensus statement on diagnostic end points for infant tuberculosis vaccine trials. Clin Infect Dis 2012; 54: 493-501.
17. Wiker H G, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992; 56: 648-661.
18. Skjot R L V, Oettinger T, Rosenkrands I, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000; 68: 214-220.
19. Houben D, Demangel C, van Ingen J, et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 2012; 14: 1287-1298.
20. Barker L, Hessel L, Walker B. Rational approach to selection and clinical development of TB vaccine candidates. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S25-S29.
21. Brennan M J, Clagett B, Fitzgerald H, et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012; 30 (18): 2811-2823.
22. Skeiky Y A W, Alderson M R, Ovendale P J, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, M. tuberculosis 72F, delivered as naked DNAor recombinant protein. J Immunol 2004; 172: 7618-7628.
23. Tsenova L, Ellison E, Harbacheuski R, et al. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 2005; 192: 98-106.
24. Capuano S V III, Croix D A, Pawar S, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003; 71: 5831-5844.
25. Dharmadhikari A S, Basaraba R J, Van Der Walt M L, et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) 2011; 91: 329-338.
26. Ameni G, Vordermeier M, Firdessa R, et al. Mycobacterium tuberculosis infection in grazing cattle in central Ethiopia. Vet J 2011; 188: 359-361.
27. Young D, Verreck F A W. Creativity in tuberculosis research and discovery. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S14-S16.
28. Minassian A M, Satti I, Poulton I D, Meyer J, Hill A V, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis 2012; 205: 1035-1042.
29. Hoft D F, Leonardi C, Milligan T, et al. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination. Clin Infect Dis 1999; 28: 785-790.
30. Lew J M, Kapopoulou A, Jones L M, Cole S T. TubercuList: 10 years after. Tuberculosis (Edinb) 2011; 91: 1-7.
31. Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extra-pulmonary dissemination. Nature 2001; 412: 190-194.
32. Temmerman S, Pethe K, Parra M, et al. Methylation-dependent T-cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 2004; 10: 935-941.
33. Rouanet C, Debrie A S, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009; 11: 995-1001.
34. Hansen S G, Vieville C, Whizin N, et al. Effector-memory T-cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge. Nat Med 2009; 15: 293-299.
35. Hansen S G, Ford J C, Lewis M S, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473: 523-527.
36. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4: 115ra2.
37. Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010; 29: 256-265.
38. Li Z M, Song D, Zhang H Y, et al. Improved humoral immunity against tuberculosis ESAT-6 antigen by chimeric DNA prime and protein boost strategy. DNA Cell Biol 2006; 25: 25-30.
39. Spencer A J, Hill F, Honeycutt J D, et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS ONE 2012; 7: e33555.
40. Martin C, Williams A, Hernandez-Pando R, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006; 24: 3408-3419.
41. Derrick S C, Evering T H, Sambandamurthy V K, et al. Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology 2007; 120: 192-206.
42. Sweeney K A, Dao D N, Goldberg M F, et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011; 17: 1261-1268.
43. Abu-Raddad L J, Sabatelli L, Achterberg J T, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 13980-13985.
44. Scriba T J, Tameris M, Smit E, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012; 185: 769-778.
45. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007; 15: 7-13.
46. Gagneux S, Small P M. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-337.
47. Ottenhoff T H M, Ellner J J, Kaufmann S H E. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S17-S20.
48. Maglione P J, Chan J. How B-cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 2009; 39: 676-686.
49. Hoft D F, Worku S, Kampmann B, et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 2002; 186: 1448-1457.
50. Brennan M J, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S6-S13.
51. Lienhardt C, Fruth U, Greco M. The blueprint for vaccine research and development: walking the path for better TB vaccines. Tuberculosis (Edinb) 2012; 92 (Suppl 1): S33-S35.